Difam Plus (diclofenac sodium + lignocaine): Uses, Dosage & Side Effects

What it's for (Indications)

This combination medication, comprising diclofenac sodium and lignocaine (lidocaine), is primarily indicated for the rapid and effective management of acute painful inflammatory conditions.
Diclofenac, a potent non-steroidal anti-inflammatory drug (NSAID), targets the underlying inflammation, while lignocaine, a local anesthetic, provides immediate pain relief at the site of administration or affected area.
Specific indications often include, but are not limited to, acute musculoskeletal pain (such as sprains, strains, low back pain), post-operative pain, acute gout attacks, renal colic, and exacerbations of rheumatoid arthritis or osteoarthritis.
The synergistic action aims to provide quick symptomatic relief alongside sustained anti-inflammatory effects, making it suitable for situations where both immediate analgesia and reduction of inflammation are crucial for patient comfort and recovery.
This combination is typically used for short-term management of acute conditions.

Dosage Information

Type	Guideline
Standard	The dosage regimen for diclofenac sodium + lignocaine preparations typically depends on the specific formulation (e.g., intramuscular injection, topical gel) and the severity of the condition being treated, as well as the patient's age and overall health status. For intramuscular injections, common adult dosages often involve 75 mg of diclofenac sodium combined with a suitable concentration of lignocaine (e.g., 1% or 2%) administered once or twice daily. The lignocaine component in injectable formulations helps to reduce injection site pain, thereby improving patient comfort during administration. Treatment duration should be as short as possible to minimize potential adverse effects and should not generally exceed a few days for acute conditions. It is crucial to adhere strictly to the prescribing physician's instructions and not exceed the recommended dose or duration of therapy. Special consideration must be given to patients with renal, hepatic, or cardiovascular impairments, where dose adjustments, reduced frequency, or close monitoring may be necessary to mitigate risks of systemic accumulation and toxicity.

Type

Guideline

Standard

The dosage regimen for diclofenac sodium + lignocaine preparations typically depends on the specific formulation (e.g., intramuscular injection, topical gel) and the severity of the condition being treated, as well as the patient's age and overall health status. For intramuscular injections, common adult dosages often involve 75 mg of diclofenac sodium combined with a suitable concentration of lignocaine (e.g., 1% or 2%) administered once or twice daily. The lignocaine component in injectable formulations helps to reduce injection site pain, thereby improving patient comfort during administration. Treatment duration should be as short as possible to minimize potential adverse effects and should not generally exceed a few days for acute conditions. It is crucial to adhere strictly to the prescribing physician's instructions and not exceed the recommended dose or duration of therapy. Special consideration must be given to patients with renal, hepatic, or cardiovascular impairments, where dose adjustments, reduced frequency, or close monitoring may be necessary to mitigate risks of systemic accumulation and toxicity.

Safety & Warnings

Common Side Effects

The combination of diclofenac sodium and lignocaine can lead to a range of side effects, reflecting the pharmacological actions of both components.
Common adverse reactions associated with diclofenac include gastrointestinal disturbances such as nausea, vomiting, dyspepsia, abdominal pain, diarrhea, or constipation.
More serious gastrointestinal events, including ulceration, bleeding, and perforation, can occur, especially with prolonged use or in susceptible individuals.
Cardiovascular risks, such as an increased risk of thrombotic events, myocardial infarction, and stroke, are significant concerns with NSAID use.
Other potential diclofenac-related effects include headache, dizziness, vertigo, elevated liver enzymes, fluid retention, and renal impairment (e.
g.
, acute kidney injury).
Lignocaine, particularly with systemic absorption or higher doses, can cause central nervous system effects like lightheadedness, dizziness, drowsiness, tinnitus, blurred vision, tremors, and, in severe cases, seizures or coma.
Cardiovascular effects from lignocaine can include bradycardia, hypotension, and cardiac arrest.
Local reactions at the injection site, such as pain, swelling, induration, or redness, are also possible.
Hypersensitivity reactions to either component can occur, ranging from skin rashes, urticaria, to severe anaphylaxis or angioedema.
Patients should report any unusual or severe symptoms immediately to their healthcare provider for prompt evaluation and management.

Serious Warnings

Black Box Warning: BLACK BOX WARNING CARDIOVASCULAR THROMBOTIC EVENTS: Non-steroidal anti-inflammatory drugs (NSAIDs), including diclofenac, cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Patients with known cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Diclofenac-containing products are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. GASTROINTESTINAL RISK: NSAIDs, including diclofenac, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding are at greater risk for serious GI events.
This combination medication requires careful consideration due to the potential for significant adverse effects stemming from both diclofenac and lignocaine.
Patients with a history of gastrointestinal ulceration, bleeding, or inflammatory bowel disease are at increased risk for serious GI complications, including perforation, and should use this medication with extreme caution or avoid it entirely.
Cardiovascular risks, including the potential for thrombotic events, hypertension, and fluid retention, necessitate careful monitoring, especially in patients with pre-existing cardiac conditions, hypertension, or a history of heart failure.
Renal function should be regularly assessed, as NSAIDs can cause acute kidney injury, particularly in dehydrated patients or those with pre-existing renal compromise.
Hepatic function should also be monitored due to the risk of liver enzyme elevation or rare severe hepatotoxicity.
For the lignocaine component, excessive systemic absorption can lead to central nervous system excitation or depression, as well as cardiovascular toxicity; therefore, caution is advised in patients with compromised cardiac function, severe liver disease, or epilepsy.
This medication should not be used in the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus and potential adverse effects on labor.
Patients should be advised about potential interactions with other medications, including anticoagulants, antiplatelet agents, corticosteroids, selective serotonin reuptake inhibitors (SSRIs), and other NSAIDs, as these can increase the risk of bleeding or other adverse effects.
Concurrent use with other nephrotoxic drugs or medications affecting electrolyte balance should also be managed cautiously.

How it Works (Mechanism of Action)

The therapeutic efficacy of this combination drug, comprising diclofenac sodium and lignocaine, arises from the distinct yet complementary mechanisms of its two active constituents. Diclofenac sodium is a non-steroidal anti-inflammatory drug (NSAID) that exerts its primary action by inhibiting the cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2 isoforms. This inhibition leads to a significant reduction in the synthesis of prostaglandins, which are crucial lipid mediators involved in the pathogenesis of pain, inflammation, and fever. By attenuating prostaglandin production, diclofenac effectively reduces inflammatory responses, swelling, and provides potent analgesic and antipyretic effects. Lignocaine (lidocaine), on the other hand, is an amide-type local anesthetic. Its mechanism involves stabilizing neuronal membranes by inhibiting the ionic fluxes, specifically the rapid influx of sodium ions through voltage-gated sodium channels, required for the initiation and conduction of nerve impulses. This blockade prevents the propagation of action potentials along nerve fibers, thereby inhibiting the transmission of pain signals from the peripheral nervous system to the central nervous system, providing rapid and localized pain relief. When combined, lignocaine offers immediate symptomatic relief, while diclofenac addresses the underlying inflammatory process, resulting in a powerful dual-action approach to acute pain and inflammation, providing both immediate comfort and sustained therapeutic effects.